In today's article we are going to talk about Nicardipine, a topic that has gained great relevance in recent years. Nicardipine is a topic that has captured the attention of experts and fans alike, due to its impact on various aspects of society. Since its appearance, Nicardipine has sparked debates and discussions around its importance and relevance in today's world. In this article, we will explore different perspectives and approaches on Nicardipine, with the aim of providing a comprehensive and enriching vision on this topic that interests so many people.
Antihypertensive drug of the calcium channel blocker class
Its mechanism of action and clinical effects closely resemble those of nifedipine and the other dihydropyridine calcium channel blockers (amlodipine, felodipine), except that nicardipine is more selective for cerebral and coronary blood vessels. It is primarily a peripheral arterial vasodilator, thus unlike the nitrovasodilators (nitroglycerin and nitroprusside), cardiac preload is minimally affected. It has the longest duration among parenteral CCBs. As its use may lead to reflex tachycardia, it is advisable to use it in conjunction with a beta-blocker.
It was patented in 1973 and approved for medical use in 1981.
Nicardipine was approved by the FDA in December 1988. The patent for both Cardene and Cardene SR expired in October 1995.
^Huang RI, Patel P, Walinsky P, Fischman DL, Ogilby JD, Awar M, et al. (November 2006). "Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention". Catheterization and Cardiovascular Interventions. 68 (5): 671–676. doi:10.1002/ccd.20885. PMID17034064. S2CID37071966.
^ abFreeman BS (2014). "Vasodilators". In Freeman BS, Berger JS (eds.). Anesthesiology Core Review: Part One Basic Exam. McGraw Hill. ISBN978-0-07-182137-7.